Biology And Treatment Of Leukemia And Bone Marrow Neoplasms

This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students.

This book is a printed edition of the Special Issue "The Biology and Treatment of Myeloid Leukaemias" that was published in IJMS

Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.

The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists. This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments. Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome positive ALL with the advent of the tyrosine kinase inhibitors. This is the first book to focus exclusively on the adult ALL patient. It provides a complete overview of diagnosis, molecular pathogenesis, evaluation, and treatment for this important patient population.

This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.

This book summarizes the latest findings about the role of cancer stem cells (CSCs) in cancer biology and how this knowledge could be used for novel anticancer therapies. It provides an overview of CSCs in selected malignancies with particular emphasis on hematopoietic neoplasias. It then reviews the role of CSCs in metastasis formation and initiat

Proceedings of the Seventeenth Annual Detroit Cancer Symposium, held in Detroit, Michigan, April 12-13, 1984

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) - including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PM) - are clonal stem cell disorders characterized by acquired activating mutations which result in an excessive production of red blood cells, platelets, and neutrophils. Recent advances in the understanding of the molecular biology and genomics of MPNs have led to the development of novel targeted treatment approaches; however, the high rate of life-threatening vascular events and the high risk of disease progression with myelofibrotic and leukemic transformation continue to present challenges in the management of MPNs. Thereby, there remains a need for novel treatment strategies. Recently, research has revealed a role for clonal hematopoiesis, driver mutations and inflammation in thrombosis risk, which may provide a basis for novel thrombosis-prevention strategies.

Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part B, Volume 366 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors. Sections cover Genetic and Sex predisposition to MPN, Transcriptional configurations of Myeloproliferative Neoplasms, Inhibitors and therapeutic targets of MPN, Mutational landscape of blast-phase myeloproliferative neoplasm (MPN-BP) and antecedent MPN, and Lessons from Mouse model of MPN, Lab tests for MPN. Publishes only invited review articles on selected topics Authored by established and active cell and molecular biologists from international sources Offers a wide range of perspectives on specific subjects

In Chronic Leukemias and Lymphomas: Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of these chronic myeloproliferative and lymphoproliferative disorders, the authors emphasize such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology.